PT2442821T - Administração segura de desmopressina - Google Patents
Administração segura de desmopressina Download PDFInfo
- Publication number
- PT2442821T PT2442821T PT107900532T PT10790053T PT2442821T PT 2442821 T PT2442821 T PT 2442821T PT 107900532 T PT107900532 T PT 107900532T PT 10790053 T PT10790053 T PT 10790053T PT 2442821 T PT2442821 T PT 2442821T
- Authority
- PT
- Portugal
- Prior art keywords
- desmopressin
- spray
- droplets
- dose
- intranasal
- Prior art date
Links
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title claims description 156
- 229960004281 desmopressin Drugs 0.000 title claims description 151
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title claims 7
- 239000007921 spray Substances 0.000 claims description 108
- 239000000203 mixture Substances 0.000 claims description 75
- 230000002686 anti-diuretic effect Effects 0.000 claims description 29
- FKUPPRZPSYCDRS-UHFFFAOYSA-N Cyclopentadecanolide Chemical compound O=C1CCCCCCCCCCCCCCO1 FKUPPRZPSYCDRS-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000003961 penetration enhancing agent Substances 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 146
- 239000003814 drug Substances 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 229940079593 drug Drugs 0.000 description 43
- 238000009472 formulation Methods 0.000 description 34
- 239000003623 enhancer Substances 0.000 description 31
- 210000002700 urine Anatomy 0.000 description 28
- 239000000047 product Substances 0.000 description 23
- 229940097496 nasal spray Drugs 0.000 description 20
- 239000007922 nasal spray Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 206010021036 Hyponatraemia Diseases 0.000 description 15
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 229940124538 antidiuretic agent Drugs 0.000 description 14
- 239000003160 antidiuretic agent Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 238000005303 weighing Methods 0.000 description 13
- 238000009826 distribution Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 208000008967 Enuresis Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000004400 mucous membrane Anatomy 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 206010030302 Oliguria Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000011224 negative regulation of urine volume Effects 0.000 description 10
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000003928 nasal cavity Anatomy 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 108010004977 Vasopressins Proteins 0.000 description 7
- 102000002852 Vasopressins Human genes 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229960003726 vasopressin Drugs 0.000 description 7
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003833 bile salt Substances 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- -1 diamidines Chemical class 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 5
- 206010029446 nocturia Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- MLSVJHOYXJGGTR-IFHOVBQLSA-N acetic acid;(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,1 Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 MLSVJHOYXJGGTR-IFHOVBQLSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229940093761 bile salts Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003595 mist Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229940124633 peptidic drug Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960002845 desmopressin acetate Drugs 0.000 description 2
- 229940084317 desmopressin nasal spray Drugs 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229940028441 minirin Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229920006395 saturated elastomer Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- RUDATBOHQWOJDD-UZVSRGJWSA-M ursodeoxycholate Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-M 0.000 description 2
- 229940014499 ursodeoxycholate Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methoxysalicylic acid Chemical compound COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000012988 Dithioester Substances 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 description 1
- FUJLYHJROOYKRA-QGZVFWFLSA-N O-lauroyl-L-carnitine Chemical compound CCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FUJLYHJROOYKRA-QGZVFWFLSA-N 0.000 description 1
- FNPHNLNTJNMAEE-HSZRJFAPSA-N O-octadecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C FNPHNLNTJNMAEE-HSZRJFAPSA-N 0.000 description 1
- PSHXNVGSVNEJBD-LJQANCHMSA-N O-tetradecanoyl-L-carnitine Chemical compound CCCCCCCCCCCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C PSHXNVGSVNEJBD-LJQANCHMSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 208000028235 central diabetes insipidus Diseases 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-M chenodeoxycholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-M 0.000 description 1
- 229940009025 chenodeoxycholate Drugs 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- LXJDKGYSHYYKFJ-UHFFFAOYSA-N cyclohexadecanone Chemical compound O=C1CCCCCCCCCCCCCCC1 LXJDKGYSHYYKFJ-UHFFFAOYSA-N 0.000 description 1
- 229940009979 dehydrocholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 150000001470 diamides Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000005022 dithioester group Chemical group 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036514 plasma sodium concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- IWQPOPSAISBUAH-VOVMJQHHSA-M sodium;2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonate Chemical compound [Na+].C1C[C@@H](O)[C@@H](C)[C@@H]2CC[C@]3(C)[C@@]4(C)C[C@H](C(C)=O)/C(=C(C(=O)NCCS([O-])(=O)=O)/CCCC(C)C)[C@@H]4C[C@@H](O)[C@H]3[C@]21C IWQPOPSAISBUAH-VOVMJQHHSA-M 0.000 description 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- BHTRKEVKTKCXOH-BJLOMENOSA-N taurochenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-BJLOMENOSA-N 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Mechanical Engineering (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26895409P | 2009-06-18 | 2009-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2442821T true PT2442821T (pt) | 2017-09-29 |
Family
ID=43356719
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107900532T PT2442821T (pt) | 2009-06-18 | 2010-06-15 | Administração segura de desmopressina |
| PT192020832T PT3679941T (pt) | 2009-06-18 | 2010-06-15 | Administração segura de desmopressina |
| PT221891294T PT4104848T (pt) | 2009-06-18 | 2010-06-15 | Administração segura de desmopressina |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT192020832T PT3679941T (pt) | 2009-06-18 | 2010-06-15 | Administração segura de desmopressina |
| PT221891294T PT4104848T (pt) | 2009-06-18 | 2010-06-15 | Administração segura de desmopressina |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9539302B2 (enExample) |
| EP (4) | EP2442821B2 (enExample) |
| JP (3) | JP6073678B2 (enExample) |
| KR (2) | KR102059255B1 (enExample) |
| CN (2) | CN102647993A (enExample) |
| AU (2) | AU2010260211B2 (enExample) |
| BR (1) | BRPI1015046A2 (enExample) |
| CA (1) | CA2765221C (enExample) |
| DK (4) | DK4104848T3 (enExample) |
| ES (4) | ES2638815T5 (enExample) |
| MX (1) | MX343193B (enExample) |
| PL (4) | PL3679941T3 (enExample) |
| PT (3) | PT2442821T (enExample) |
| RU (2) | RU2015144851A (enExample) |
| WO (1) | WO2010147981A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
| AU2008283929B2 (en) | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| PT2381923T (pt) * | 2008-12-22 | 2018-11-13 | Serenity Pharmaceuticals Llc | Administração intranasal de desmopressina |
| ES2638815T5 (en) | 2009-06-18 | 2025-06-26 | Acerus Pharmaceuticals Usa Llc | Safe desmopressin administration |
| US9119773B2 (en) * | 2011-06-27 | 2015-09-01 | Board Of Regents, The University Of Texas System | Toroidal pharmaceutical formulations |
| WO2014055801A1 (en) * | 2012-10-05 | 2014-04-10 | Henkin Robert I | Phosphodiesterase inhibitors for treating taste and smell disorders |
| ES2744542T3 (es) * | 2013-03-15 | 2020-02-25 | Robert I Henkin | Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| US9925232B2 (en) * | 2013-07-23 | 2018-03-27 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| JP2017535567A (ja) * | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| ES2802530T3 (es) * | 2015-08-04 | 2021-01-20 | Windstar Medical Gmbh | Una composición nasal |
| EP3897603A4 (en) | 2018-12-19 | 2022-09-14 | Grace Therapeutics Inc. | THERAPEUTIC COMPOSITION OF INTRANASAL LIDOCAINE |
| JP7606530B2 (ja) | 2020-03-24 | 2024-12-25 | シラノ セラピューティクス， インコーポレイテッド | コロナウイルス感染症による化学感覚機能障害の治療 |
| USD959279S1 (en) | 2020-04-07 | 2022-08-02 | VB Brands LLC | Spray bottle |
| US11272834B2 (en) * | 2020-04-13 | 2022-03-15 | AIMIC Corp. | Imaging system and method for quality and dosage control of anesthetics applied by a spray nozzle |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS171787B1 (enExample) | 1973-11-09 | 1976-11-29 | ||
| US4148787A (en) | 1976-05-24 | 1979-04-10 | Ferring Ab | Antidiuretically effective polypeptide and a process for preparing the same |
| US4285858A (en) | 1979-10-30 | 1981-08-25 | Mt. Sinai School Of Medicine Of The City University Of N.Y. | Vasopressin analogs |
| US4263283A (en) | 1980-05-16 | 1981-04-21 | Ferring Pharmaceuticals, Inc. | Method for prophylaxis and/or treatment of sickle cell disease |
| CA1208558A (en) | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
| US4771769A (en) | 1982-12-20 | 1988-09-20 | Schering Corporation | Hand held metered spray dispenser |
| US4548922A (en) | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
| US4746508A (en) | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
| SE8306367L (sv) | 1983-11-18 | 1985-05-19 | Ferring Ab | Antidiuretiskt verkande farmaceutiskt preparat |
| US4863737A (en) | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JP2583777B2 (ja) | 1985-12-04 | 1997-02-19 | シエ−，デイ−ン | 医薬品の経皮施与 |
| US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4878892A (en) | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| US5112804A (en) | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
| US4944429A (en) | 1987-08-28 | 1990-07-31 | Schering Corporation | Manually-operable spray dispenser with locking mechanism |
| US5350741A (en) | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
| US5154122A (en) | 1989-10-20 | 1992-10-13 | Sol Goldschmidt | Shipping device for suspended piece goods |
| JP2951681B2 (ja) | 1990-02-23 | 1999-09-20 | 株式会社資生堂 | 経粘膜投与用薬剤組成物 |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| CN1060980A (zh) | 1990-10-26 | 1992-05-13 | 蔡东林 | 多用电控自控微型喷雾器 |
| US5314694A (en) | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
| US5122383A (en) | 1991-05-17 | 1992-06-16 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5227169A (en) | 1991-05-17 | 1993-07-13 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| US5212199A (en) | 1991-05-17 | 1993-05-18 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| AU653026B2 (en) | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
| US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
| US5298256A (en) | 1992-04-28 | 1994-03-29 | Corint, Ltd. | Desmopressin buccal patch composition |
| IT1255895B (it) | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
| CA2090738C (en) | 1993-02-24 | 1996-05-21 | Hema-Quebec | Use of paf |
| SE9300937L (sv) | 1993-03-19 | 1994-09-20 | Anne Fjellestad Paulsen | Komposition för oral administrering av peptider |
| CN1101701C (zh) | 1993-06-29 | 2003-02-19 | 凡林有限公司 | 由鼻给药的去氨加压素组合物及其制备方法和用途 |
| PT710243E (pt) | 1993-06-29 | 2000-11-30 | Ferring Bv | Sintese melhorada de peptidos ciclicos. |
| US5482931A (en) | 1993-06-29 | 1996-01-09 | Ferring Ab | Stabilized pharmaceutical peptide compositions |
| US5500413A (en) | 1993-06-29 | 1996-03-19 | Ferring Ab | Process for manufacture of 1-deamino-8-D-arginine vasopressin |
| US5985835A (en) | 1993-12-23 | 1999-11-16 | Ferring B.V. | Desmopressin for nocturia, incontinence and enuresis |
| US5388766A (en) * | 1993-09-22 | 1995-02-14 | The Procter & Gamble Company | High pressure atomization systems for high viscosity products |
| US5358551A (en) | 1993-11-16 | 1994-10-25 | Ccpi, Inc. | Turbulence inhibiting tundish and impact pad and method of using |
| JPH09510182A (ja) | 1993-11-17 | 1997-10-14 | エルディーエス・テクノロジーズ・インコーポレーテッド | カプセル封入されたドラッグデリバリー用透明液 |
| AU1677095A (en) | 1994-01-11 | 1995-08-01 | Alkermes Controlled Therapeutics, Inc. | Oral dosage form of desmopressin (ddavp) |
| US5576014A (en) | 1994-01-31 | 1996-11-19 | Yamanouchi Pharmaceutical Co., Ltd | Intrabuccally dissolving compressed moldings and production process thereof |
| SE9400918L (sv) | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
| US5613770A (en) | 1994-05-16 | 1997-03-25 | Lite Corporation | Apparatus for securing component panels in a lighting fixture |
| WO1996040332A1 (en) | 1995-06-07 | 1996-12-19 | O'neil, Christine | Patient controlled drug delivery device |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| US5849322A (en) | 1995-10-23 | 1998-12-15 | Theratech, Inc. | Compositions and methods for buccal delivery of pharmaceutical agents |
| DE19610457A1 (de) | 1996-03-16 | 1997-09-18 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| DE19623030A1 (de) | 1996-06-08 | 1997-12-11 | Pfeiffer Erich Gmbh & Co Kg | Austrag-Einheit für Medien |
| US5763398A (en) | 1996-06-20 | 1998-06-09 | Ferring B.V. | Nasal administration of desmopressin |
| DE19627228A1 (de) | 1996-07-05 | 1998-01-08 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| GB9614235D0 (en) | 1996-07-06 | 1996-09-04 | Danbiosyst Uk | Composition for enhanced uptake of polar drugs from mucosal surfaces |
| CN1228708A (zh) | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| DE19642976A1 (de) | 1996-10-18 | 1998-04-23 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| TR200000656T2 (tr) | 1997-09-12 | 2000-06-21 | Telefonaktiebolaget Lm Ericsson (Publ) | Mobil telefonlaşma için yöntem ve düzenleme |
| CA2302275C (en) | 1997-09-19 | 2009-12-08 | Shire Laboratories, Inc. | Solid solution beadlet |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| JP3422775B2 (ja) | 1998-07-08 | 2003-06-30 | キリン−アムジエン・インコーポレーテツド | 高分子医薬品含有粉末状経粘膜投与製剤 |
| US6355270B1 (en) | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
| ATE390960T1 (de) | 1999-02-14 | 2008-04-15 | Pfeiffer Erich Gmbh & Co Kg | Spender für fliessfähige medien |
| AR014640A1 (es) | 1999-02-23 | 2001-03-28 | Univ Nac Quilmes | UNA COMPOSICíoN FARMACÉUTICA INHIBIDORA DE LA DISEMINACIoN METASTÁSICA DURANTE LA CIRUGíA DE UN TUMOR CANCEROSO, UN PROCEDIMENTO DE PREPARACIoN Y UN KIT PARA UNA FORMULACIoN INYECTABLE. |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| CA2377566C (en) * | 1999-05-20 | 2007-08-07 | Iep Pharmaceutical Devices, Inc. | Low spray force, low retention atomization system |
| DE19938798A1 (de) | 1999-08-16 | 2001-03-01 | Pfeiffer Erich Gmbh & Co Kg | Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte |
| DE19940236A1 (de) | 1999-08-25 | 2001-03-08 | Pfeiffer Erich Gmbh & Co Kg | Spender mit manuell betätigbarer Ausbringeinrichtung |
| DE19942792A1 (de) | 1999-09-08 | 2001-03-15 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| RU2216319C1 (ru) | 1999-11-30 | 2003-11-20 | Панацея Биотек Лимитед | Быстрорастворимая фармацевтическая композиция в виде твердой лекарственной формы с пролонгированным сладким вкусом и способ ее получения |
| WO2002013782A1 (en) | 2000-08-11 | 2002-02-21 | Hyundai Pharmaceutical Ind. Co., Ltd | Oral delivery of peptide |
| GB0028575D0 (en) | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
| DE10110742A1 (de) | 2001-02-28 | 2002-09-05 | Pfeiffer Erich Gmbh & Co Kg | Spender für Medien |
| US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| WO2003026803A1 (de) | 2001-09-21 | 2003-04-03 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung mit einer pumpvorrichtung |
| BR0212901B1 (pt) | 2001-09-21 | 2011-12-13 | dispositivo dosador com um reservatório de meio, bem como dispositivo de bomba para um dispositivo dosador. | |
| US20050127107A1 (en) | 2001-09-21 | 2005-06-16 | Pierre Mbonyumuhire | Dosing device with a medium reservoir and a pump device |
| US20050025824A1 (en) | 2001-12-14 | 2005-02-03 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
| CA2471081A1 (en) | 2001-12-19 | 2003-07-03 | Alza Corporation | Formulation & dosage form for the controlled delivery of therapeutic agents |
| CN100450547C (zh) | 2002-01-16 | 2009-01-14 | 安斯泰来制药有限公司 | 改善口服吸收用药物组合物 |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| HRP20041152B1 (hr) | 2002-05-07 | 2008-01-31 | Ferring B.V. | Farmaceutske formulacije |
| US20090035260A1 (en) | 2002-07-29 | 2009-02-05 | Therapicon Srl | Enhanced nasal composition of active peptide |
| ITMI20021684A1 (it) | 2002-07-29 | 2004-01-29 | Therapicon Srl | Composizione farmaceutica di peptide nasale |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| CN1233952C (zh) | 2003-09-04 | 2005-12-28 | 上海交通大学 | 调节入口烟气流量分配的辐射屏式过热器 |
| EP2322195A2 (en) | 2003-11-10 | 2011-05-18 | Reprise Biopharmaceutics, LLC | Pharmaceutical compositions including low dosages of desmopressin |
| CN101829319A (zh) | 2003-12-08 | 2010-09-15 | Cpex药品公司 | 用于胰岛素治疗的药用组合物及方法 |
| AU2004311478A1 (en) | 2003-12-31 | 2005-07-21 | Cydex Pharmaceuticals, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20060046962A1 (en) * | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| DE102004044344A1 (de) | 2004-09-09 | 2006-03-30 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung |
| DE102004050679A1 (de) | 2004-10-13 | 2006-04-20 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung |
| DE102004050977A1 (de) | 2004-10-14 | 2006-04-20 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung für wenigstens ein Medium |
| WO2006134055A1 (fr) | 2005-06-17 | 2006-12-21 | France Telecom | Procede de gestion de l'execution par un serveur d'une application offrant au moins un service multimedia interactif a au moins un terminal, produit programme d'ordinateur et serveur correspondants |
| WO2007022345A2 (en) | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| CN1785448A (zh) | 2005-11-11 | 2006-06-14 | 广东工业大学 | 医用防染式药雾吸入喷嘴 |
| DE102006008874B4 (de) | 2006-02-21 | 2012-06-21 | Ing. Erich Pfeiffer Gmbh | Dosiervorrichtung mit einer manuell betätigbaren Pumpeinrichtung |
| EP2035031A4 (en) | 2006-06-08 | 2010-02-24 | Cpex Pharmaceuticals Inc | INSULIN COMPOSITION |
| US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
| CN106038481A (zh) * | 2007-06-28 | 2016-10-26 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| AU2008283929B2 (en) | 2007-08-06 | 2013-10-10 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
| PT2381923T (pt) * | 2008-12-22 | 2018-11-13 | Serenity Pharmaceuticals Llc | Administração intranasal de desmopressina |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| ES2638815T5 (en) | 2009-06-18 | 2025-06-26 | Acerus Pharmaceuticals Usa Llc | Safe desmopressin administration |
| TWI598335B (zh) | 2012-10-25 | 2017-09-11 | Ｗ Ｒ 康格雷氏公司 | 用於製造吡啶及其烷基衍生物之改良方法、觸媒 |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
-
2010
- 2010-06-15 ES ES10790053T patent/ES2638815T5/es active Active
- 2010-06-15 DK DK22189129.4T patent/DK4104848T3/da active
- 2010-06-15 RU RU2015144851A patent/RU2015144851A/ru unknown
- 2010-06-15 WO PCT/US2010/038663 patent/WO2010147981A1/en not_active Ceased
- 2010-06-15 BR BRPI1015046A patent/BRPI1015046A2/pt active Search and Examination
- 2010-06-15 PL PL19202083.2T patent/PL3679941T3/pl unknown
- 2010-06-15 CN CN2010800368757A patent/CN102647993A/zh active Pending
- 2010-06-15 EP EP10790053.2A patent/EP2442821B2/en active Active
- 2010-06-15 DK DK17168865.8T patent/DK3278809T3/da active
- 2010-06-15 CN CN201810151092.1A patent/CN108295241A/zh active Pending
- 2010-06-15 JP JP2012516198A patent/JP6073678B2/ja active Active
- 2010-06-15 US US13/378,778 patent/US9539302B2/en active Active
- 2010-06-15 ES ES17168865T patent/ES2773694T3/es active Active
- 2010-06-15 EP EP22189129.4A patent/EP4104848B1/en active Active
- 2010-06-15 RU RU2012101619/15A patent/RU2569756C2/ru active
- 2010-06-15 PL PL17168865T patent/PL3278809T3/pl unknown
- 2010-06-15 PT PT107900532T patent/PT2442821T/pt unknown
- 2010-06-15 EP EP17168865.8A patent/EP3278809B1/en not_active Revoked
- 2010-06-15 DK DK10790053.2T patent/DK2442821T4/da active
- 2010-06-15 CA CA2765221A patent/CA2765221C/en active Active
- 2010-06-15 PL PL10790053.2T patent/PL2442821T5/pl unknown
- 2010-06-15 ES ES19202083T patent/ES2929471T3/es active Active
- 2010-06-15 PT PT192020832T patent/PT3679941T/pt unknown
- 2010-06-15 ES ES22189129T patent/ES2969281T3/es active Active
- 2010-06-15 DK DK19202083.2T patent/DK3679941T3/da active
- 2010-06-15 PL PL22189129.4T patent/PL4104848T3/pl unknown
- 2010-06-15 MX MX2012000066A patent/MX343193B/es active IP Right Grant
- 2010-06-15 KR KR1020177030947A patent/KR102059255B1/ko active Active
- 2010-06-15 KR KR1020127001287A patent/KR101792696B1/ko active Active
- 2010-06-15 EP EP19202083.2A patent/EP3679941B1/en active Active
- 2010-06-15 PT PT221891294T patent/PT4104848T/pt unknown
- 2010-06-15 AU AU2010260211A patent/AU2010260211B2/en active Active
-
2015
- 2015-10-02 JP JP2015196912A patent/JP6166320B2/ja active Active
-
2016
- 2016-06-23 AU AU2016204306A patent/AU2016204306B2/en active Active
-
2017
- 2017-01-06 US US15/400,535 patent/US11419914B2/en active Active
- 2017-06-22 JP JP2017121805A patent/JP6501826B2/ja active Active
-
2022
- 2022-08-10 US US17/885,368 patent/US12090190B2/en active Active
-
2024
- 2024-09-10 US US18/829,573 patent/US20250241977A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12090190B2 (en) | Safe desmopressin administration | |
| JP6389209B2 (ja) | 鼻腔内デスモプレシン投与 | |
| HK40084952A (en) | Safe desmopressin administration | |
| HK40084952B (en) | Safe desmopressin administration | |
| HK40060414B (en) | Safe desmopressin administration | |
| HK40060414A (en) | Safe desmopressin administration | |
| HK1250642B (en) | Safe desmopressin administration | |
| HK1250642A1 (en) | Safe desmopressin administration | |
| HK1172544A (en) | Safe desmopressin administration | |
| HK1172544B (en) | Safe desmopressin administration |